| 000 | 01882 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516190739.0 | ||
| 264 | 0 | _c20140515 | |
| 008 | 201405s 0 0 eng d | ||
| 022 | _a1879-1891 | ||
| 024 | 7 |
_a10.1016/j.ajo.2013.12.018 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHolekamp, Nancy M | |
| 245 | 0 | 0 |
_aClinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. _h[electronic resource] |
| 260 |
_bAmerican journal of ophthalmology _cApr 2014 |
||
| 300 |
_a825-833.e1 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 | _aDatabases, Factual |
| 650 | 0 | 4 |
_aDrug Utilization _xstatistics & numerical data |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFluorescein Angiography |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInsurance Claim Review |
| 650 | 0 | 4 | _aIntravitreal Injections |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMedicare Part B |
| 650 | 0 | 4 | _aRanibizumab |
| 650 | 0 | 4 | _aRetreatment |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTomography, Optical Coherence |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aVisual Acuity _xphysiology |
| 650 | 0 | 4 |
_aWet Macular Degeneration _xdiagnosis |
| 700 | 1 | _aLiu, Ying | |
| 700 | 1 | _aYeh, Wei-Shi | |
| 700 | 1 | _aChia, Yifeng | |
| 700 | 1 | _aKiss, Szilárd | |
| 700 | 1 | _aAlmony, Arghavan | |
| 700 | 1 | _aKowalski, Jonathan W | |
| 773 | 0 |
_tAmerican journal of ophthalmology _gvol. 157 _gno. 4 _gp. 825-833.e1 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ajo.2013.12.018 _zAvailable from publisher's website |
| 999 |
_c23415702 _d23415702 |
||